scispace - formally typeset
P

Paulette Mhawech-Fauceglia

Researcher at Roswell Park Cancer Institute

Publications -  86
Citations -  4520

Paulette Mhawech-Fauceglia is an academic researcher from Roswell Park Cancer Institute. The author has contributed to research in topics: Cancer & Ovarian cancer. The author has an hindex of 33, co-authored 82 publications receiving 4033 citations. Previous affiliations of Paulette Mhawech-Fauceglia include New Zealand Institute for Crop and Food Research & Geneva College.

Papers
More filters
Journal ArticleDOI

Tumor-infiltrating NY-ESO-1–specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer

TL;DR: Dual blockade of LAG-3 and PD-1 during T-cell priming efficiently augmented proliferation and cytokine production by NY-ESO-1–specific CD8+ T cells, indicating that antitumor function of NY-eso-1-specific CD 8+ T Cells could potentially be improved by therapeutic targeting of these inhibitory receptors.
Journal ArticleDOI

Ovarian Cancer Spheroid Cells with Stem Cell-Like Properties Contribute to Tumor Generation, Metastasis and Chemotherapy Resistance through Hypoxia-Resistant Metabolism

TL;DR: In insight into the relationship between tumor dissemination and metabolic attributes of human cancer stem cells, spheroid cells were found to be enriched for cells with cancer stem cell-like characteristics and contributed to tumor generation, progression and chemotherapy resistance.
Journal ArticleDOI

Prostate‐specific membrane antigen (PSMA) protein expression in normal and neoplastic tissues and its sensitivity and specificity in prostate adenocarcinoma: an immunohistochemical study using mutiple tumour tissue microarray technique

TL;DR: The objective is to determine prostate‐specific membrane antigen (PSMA) expression in normal tissues and in 3161 benign and malignant tumours and subsequently to define its sensitivity and specificity in prostatic adenocarcinoma (PaC).
Journal ArticleDOI

Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer

TL;DR: Results confirm the paradigm that the provision of cognate CD4+ T cell help is important for cancer vaccine design and provides the rationale for a phase II study design using ESO157–170 epitope or the full-length NY-ESO-1 protein for immunotherapy in patients with EOC.